Almirall LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.6M | 581 | 54.3% |
| Consulting Fee | $1.9M | 753 | 18.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 677 | 14.0% |
| Food and Beverage | $966,932 | 42,581 | 9.4% |
| Travel and Lodging | $239,983 | 578 | 2.3% |
| Grant | $108,840 | 1 | 1.1% |
| Honoraria | $24,100 | 10 | 0.2% |
| Education | $1,883 | 160 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| M14867-32 | $1.3M | 2 | 201 |
| Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES) | $537,956 | 32 | 147 |
| KLISYRI-IIS US Biomarkers Seykora | $435,617 | 1 | 3 |
| H2200518 - SEYSARA-IIS Dr. Bunick MOA Study | $330,607 | 0 | 2 |
| THE USE OF Sarecycline IN THE TREATMENT OF ROSACEA | $322,373 | 0 | 2 |
| SEYSARA IN THE TREATMENT OF ROSACEA | $322,373 | 0 | 1 |
| Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis (PROAK) | $265,401 | 4 | 58 |
| Elucidating Novel Therapeutic Targets in Hidradenitis Suppurativa | $247,569 | 0 | 4 |
| Mode of action of sarecycline on the bacterial ribosome | $236,984 | 0 | 2 |
| PROAK | $223,535 | 1 | 33 |
| M-27134-01 | $209,035 | 0 | 89 |
| IIS Dr Kircik Patient preference comparing two CAL/BPD fixed dose combinations | $122,000 | 1 | 3 |
| Sarecycline Truncal Acne Safety and Efficacy Response (TASER) Study | $105,000 | 0 | 2 |
| A patient preference study comparing two CAL/BDP fixed dose combinations used for the topical treatment of plaque psoriasis, one formulated as a cream Wynzora and the other as a foam Enstila | $100,000 | 0 | 2 |
| H2200555 KLISYRI-IIS US Tirba SCCIS Lain | $56,058 | 0 | 1 |
| ACZONE GEL IN THE TREATMENT OF ACNE VULGARIS | $52,004 | 0 | 5 |
| PhIV-IIS - RWE Tirbanibulin NMSC | $50,000 | 0 | 2 |
| Klisyri - IIS Dr. Feldman - Investigator-initiated Study of Field of Cancerization Size | $50,000 | 0 | 2 |
| Klisyri - IIS Dr. Feldman - Investigator-initiated Study of Patient Refusal FU | $41,029 | 0 | 2 |
| ROLE OF ANTIBIOTICS IN THE TREATMENT OF ACNE VULGARIS | $40,000 | 0 | 2 |
| IIS Dr. Lain - Tirbanibulin for sBCC – US | $37,373 | 0 | 1 |
| An open-label study to investigate the efficacy and tolerability of Aczone gel, 7.5% in the treatment of acne vulgaris in men and women with Fitzpatrick skin types IV-VI | $35,478 | 0 | 1 |
| Systematic Review of safety, tolerability and patient-reported outcomes of topical treatments in actinic keratosis | $30,000 | 0 | 2 |
| Klisyri - IIS Dr. Feldman - Investigator-initiated Study of Call Backs | $30,000 | 0 | 1 |
| PhIV-IIS - RWE Tirbanibulin for Condyloma Angela Yen Moore | $28,500 | 0 | 2 |
| Research | $20,000 | 0 | 1 |
| A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis | $20,000 | 1 | 1 |
| Perioral Dermatitis IIS | $17,610 | 1 | 2 |
| AD Survey testing | $2,400 | 1 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $395,806 | $0 |
| John Seykora, Md, MD | Dermatopathology | Philadelphia, PA | $290,561 | $0 |
| Dr. Todd Schlesinger, M.d, M.D | Dermatology | Charleston, SC | $214,914 | $0 |
| Dr. Susan Walker, M.d, M.D | Dermatology | Bethesda, MD | $166,594 | $0 |
| Dr. Edward Lain, M.d, M.D | Dermatology | Austin, TX | $162,784 | $0 |
| Dr. Angela Moore, Md, Pa, MD, PA | Dermatology | Arlington, TX | $160,560 | $0 |
| Dr. Emmy Graber, M.d, M.D | Dermatology | Boston, MA | $159,830 | $0 |
| Dr. Brian Berman, M.d., Ph.d, M.D., PH.D | Dermatology | Aventura, FL | $149,830 | $0 |
| Dr. James Del Rosso, Do, DO | MOHS-Micrographic Surgery | Las Vegas, NV | $141,407 | $0 |
| Dr. Stacy Smith, M.d, M.D | Dermatology | Encinitas, CA | $136,891 | $0 |
| Dr. Lawrence Schachner, Md, MD | Dermatology | Miami, FL | $119,928 | $0 |
| Seth Orlow, M.d, M.D | Dermatology | New York, NY | $100,613 | $0 |
| Neal Bhatia, Md, MD | Dermatology | San Diego, CA | $95,758 | $0 |
| Linda Stein Gold, M.d, M.D | Dermatology | West Bloomfield, MI | $86,238 | $0 |
| Stefan Weiss, Md, MD | Dermatology | Chapel Hill, NC | $80,000 | $0 |
| Dr. Hilary Baldwin, M.d, M.D | Dermatology | Brooklyn, NY | $79,191 | $0 |
| Dr. Christopher Bunick, M.d., Ph.d, M.D., PH.D | Student in an Organized Health Care Education/Training Program | New Haven, CT | $73,468 | $0 |
| Dr. Pearl Kwong, Md Phd, MD PHD | Dermatology | Jacksonville, FL | $60,611 | $0 |
| Dr. Johann Gudjonsson, Md, MD | Dermatology | Ann Arbor, MI | $59,362 | $0 |
| Dr. Alexandra Kimball, Md Mph, MD MPH | Dermatology | Boston, MA | $58,891 | $0 |
| Lawrence Eichenfield, M.d, M.D | Pediatric Dermatology | San Diego, CA | $54,801 | $0 |
| Julie Harper, Md, MD | Dermatology | Birmingham, AL | $47,036 | $0 |
| Steven Feldman, Md, MD | Dermatology | Winston Salem, NC | $45,431 | $0 |
| Dr. Jashin Wu, M.d, M.D | Dermatology | Corona, CA | $33,993 | $0 |
| Emma Guttman, Md, MD | Dermatology | New York, NY | $33,806 | $0 |
About Almirall LLC
Almirall LLC has made $10.3M in payments to 9,438 healthcare providers, recorded across 45,341 transactions in the CMS Open Payments database. In 2024, the company paid $945,338. The top product by payment volume is Klisyri ($2.1M).
Payments were distributed across 111 medical specialties. The top specialty by payment amount is Dermatology ($4.1M to 4,066 doctors).
Payment categories include: Food & Beverage ($966,932), Consulting ($1.9M), Research ($5.6M), Travel & Lodging ($239,983).
Almirall LLC is associated with 6 products in the CMS Open Payments database, including Klisyri, Seysara, and SEYSARA.